
Agenus (AGEN) Stock Forecast & Price Target
Agenus (AGEN) Analyst Ratings
Bulls say
Agenus Inc. is well-positioned for growth due to its diverse and promising product pipeline, which includes innovative therapies aimed at harnessing the immune system to combat cancer and infections. The company's potential to generate additional revenue from the compassionate use of its antibody candidates, botensilimab and balstilimab, is bolstered by the provision of real-world clinical evidence that supports their efficacy in critical cancer indications, such as triple negative breast cancer and ER+ breast cancer. Furthermore, positive ex-US regulatory sentiment regarding these therapies enhances the company's outlook, indicating potential for broader market acceptance and validation of their clinical benefits.
Bears say
Agenus Inc faces several significant risks that contribute to a negative outlook on its stock. The potential emergence of safety signals in clinical programs, combined with the possibility of lower-than-expected efficacy in studies, undermines investor confidence in the company's ability to deliver viable products. Additionally, concerns regarding regulatory decisions, increased commercial competition, financing requirements, and the adequacy of intellectual property protections further exacerbate the challenges facing Agenus's pipeline and market position.
This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.
Agenus (AGEN) Analyst Forecast & Price Prediction
Start investing in Agenus (AGEN)
Order type
Buy in
Order amount
Est. shares
0 shares